Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Biogen Idec Ltd
Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY, UK
Telephone: +44 (0)1628 501 000
Fax: +44 (0)1628 501 010
Medical Information Direct Line: 0800 008 7401
Medical Information e-mail: biogenidec@professionalinformation.co.uk
Medical Information Fax: +44(0)1748 828801
Out of Hours Telephone: 0800 008 7401

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 28/06/2011
PIL TYSABRI 300 mg concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 28/06/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 02/12/2010 and displayed until 28/06/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 18/05/2010 and displayed until 02/12/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 02/02/2009 and displayed until 18/05/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 17/11/2008 and displayed until 02/02/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 10/07/2008 and displayed until 17/11/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 15/05/2008 and displayed until 10/07/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 03/12/2007 and displayed until 15/05/2008
Reasons for adding or updating:
  • Change to manufacturer contact details
Updated on 26/11/2007 and displayed until 03/12/2007
Reasons for adding or updating:
  • Change to manufacturer contact details
Updated on 02/02/2007 and displayed until 26/11/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Improved Electronic Presentation
Updated on 24/07/2006 and displayed until 02/02/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  natalizumab